Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 151 entries
Sorted by: Best Match Show Resources per page
Inhibition by alpha-amanitin of chromosomal ribonucleic acid synthesis in rat liver.

FEBS letters

Montecuccoli G, Novello F, Stirpe F.
PMID: 11946776
FEBS Lett. 1972 Sep 15;25(2):305-308. doi: 10.1016/0014-5793(72)80510-6.

No abstract available.

Cite
Montecuccoli G, Novello F, Stirpe F. Inhibition by alpha-amanitin of chromosomal ribonucleic acid synthesis in rat liver. FEBS Lett. 1972;25(2):305-308doi: 10.1016/0014-5793(72)80510-6.
Montecuccoli, G., Novello, F., & Stirpe, F. (1972). Inhibition by alpha-amanitin of chromosomal ribonucleic acid synthesis in rat liver. FEBS letters, 25(2), 305-308. https://doi.org/10.1016/0014-5793(72)80510-6
Montecuccoli, G, et al. "Inhibition by alpha-amanitin of chromosomal ribonucleic acid synthesis in rat liver." FEBS letters vol. 25,2 (1972): 305-308. doi: https://doi.org/10.1016/0014-5793(72)80510-6
Montecuccoli G, Novello F, Stirpe F. Inhibition by alpha-amanitin of chromosomal ribonucleic acid synthesis in rat liver. FEBS Lett. 1972 Sep 15;25(2):305-308. doi: 10.1016/0014-5793(72)80510-6. PMID: 11946776.
Copy Download .nbib Format: NLM
The therapeutic use of botulinum toxin.

Expert opinion on investigational drugs

Tugnoli V, Eleopra R, Montecucco C, De Grandis D.
PMID: 15989508
Expert Opin Investig Drugs. 1997 Oct;6(10):1383-94. doi: 10.1517/13543784.6.10.1383.

Since Alan Scott's research, botulinum toxin (BoNT) has been used in several diseases or conditions characterised by muscular overactivity. BoNT acts on either neuromuscular or autonomic cholinergic junctions. Seven different serotypes are known, with antigenic specificity and different therapeutic...

Cite
Tugnoli V, Eleopra R, Montecucco C, et al. The therapeutic use of botulinum toxin. Expert Opin Investig Drugs. 1997;6(10):1383-94doi: 10.1517/13543784.6.10.1383.
Tugnoli, V., Eleopra, R., Montecucco, C., & De Grandis, D. (1997). The therapeutic use of botulinum toxin. Expert opinion on investigational drugs, 6(10), 1383-94. https://doi.org/10.1517/13543784.6.10.1383
Tugnoli, V, et al. "The therapeutic use of botulinum toxin." Expert opinion on investigational drugs vol. 6,10 (1997): 1383-94. doi: https://doi.org/10.1517/13543784.6.10.1383
Tugnoli V, Eleopra R, Montecucco C, De Grandis D. The therapeutic use of botulinum toxin. Expert Opin Investig Drugs. 1997 Oct;6(10):1383-94. doi: 10.1517/13543784.6.10.1383. PMID: 15989508.
Copy Download .nbib Format: NLM
Sepsis by .

Case reports in infectious diseases

Caserza L, Piatti G, Bonaventura A, Liberale L, Carbone F, Dallegri F, Ottonello L, Gustinetti G, Del Bono V, Montecucco F.
PMID: 29318064
Case Rep Infect Dis. 2017;2017:2527980. doi: 10.1155/2017/2527980. Epub 2017 Nov 26.

No abstract available.

Cite
Caserza L, Piatti G, Bonaventura A, et al. Sepsis by . Case Rep Infect Dis. 2017;2017:2527980doi: 10.1155/2017/2527980.
Caserza, L., Piatti, G., Bonaventura, A., Liberale, L., Carbone, F., Dallegri, F., Ottonello, L., Gustinetti, G., Del Bono, V., & Montecucco, F. (2017). Sepsis by . Case reports in infectious diseases, 20172527980. https://doi.org/10.1155/2017/2527980
Caserza, Lara, et al. "Sepsis by ." Case reports in infectious diseases vol. 2017 (2017): 2527980. doi: https://doi.org/10.1155/2017/2527980
Caserza L, Piatti G, Bonaventura A, Liberale L, Carbone F, Dallegri F, Ottonello L, Gustinetti G, Del Bono V, Montecucco F. Sepsis by . Case Rep Infect Dis. 2017;2017:2527980. doi: 10.1155/2017/2527980. Epub 2017 Nov 26. PMID: 29318064; PMCID: PMC5727562.
Copy Download .nbib Format: NLM
Research update for articles published in EJCI in 2015.

European journal of clinical investigation

Al-Daghri NM, Batzel JJ, Burgmann H, Carbone F, Charmandari E, Chrousos GP, Distelmaier K, Cvirn G, Dullaart RPF, Dumitrascu DL, Esteve-Pastor MA, Gervasini G, Goliasch G, Goswami N, Gruppen EG, Hernández-Mijares A, Kalantaridou SN, Krause R, Latini R, Makrigiannakis A, Marín F, Masson S, Montecucco F, Ndrepepa G, Nicolaides NC, Novelli D, Orasan OH, Qorbani M, Ratzinger F, Roessler A, Sabico S, Sciatti E, Stefanaki C, Stoner L, Tabatabaei-Malazy O, Tatar E, Toz H, Uslu A, Victor VM, Vizzardi E.
PMID: 28960328
Eur J Clin Invest. 2017 Oct;47(10):775-788. doi: 10.1111/eci.12819.

No abstract available.

Cite
Al-Daghri NM, Batzel JJ, Burgmann H, et al. Research update for articles published in EJCI in 2015. Eur J Clin Invest. 2017;47(10):775-788doi: 10.1111/eci.12819.
Al-Daghri, N. M., Batzel, J. J., Burgmann, H., Carbone, F., Charmandari, E., Chrousos, G. P., Distelmaier, K., Cvirn, G., Dullaart, R. P. F., Dumitrascu, D. L., Esteve-Pastor, M. A., Gervasini, G., Goliasch, G., Goswami, N., Gruppen, E. G., Hernández-Mijares, A., Kalantaridou, S. N., Krause, R., Latini, R., Makrigiannakis, A., Marín, F., Masson, S., Montecucco, F., Ndrepepa, G., Nicolaides, N. C., Novelli, D., Orasan, O. H., Qorbani, M., Ratzinger, F., Roessler, A., Sabico, S., Sciatti, E., Stefanaki, C., Stoner, L., Tabatabaei-Malazy, O., Tatar, E., Toz, H., Uslu, A., Victor, V. M., & Vizzardi, E. (2017). Research update for articles published in EJCI in 2015. European journal of clinical investigation, 47(10), 775-788. https://doi.org/10.1111/eci.12819
Al-Daghri, Nasser M, et al. "Research update for articles published in EJCI in 2015." European journal of clinical investigation vol. 47,10 (2017): 775-788. doi: https://doi.org/10.1111/eci.12819
Al-Daghri NM, Batzel JJ, Burgmann H, Carbone F, Charmandari E, Chrousos GP, Distelmaier K, Cvirn G, Dullaart RPF, Dumitrascu DL, Esteve-Pastor MA, Gervasini G, Goliasch G, Goswami N, Gruppen EG, Hernández-Mijares A, Kalantaridou SN, Krause R, Latini R, Makrigiannakis A, Marín F, Masson S, Montecucco F, Ndrepepa G, Nicolaides NC, Novelli D, Orasan OH, Qorbani M, Ratzinger F, Roessler A, Sabico S, Sciatti E, Stefanaki C, Stoner L, Tabatabaei-Malazy O, Tatar E, Toz H, Uslu A, Victor VM, Vizzardi E. Research update for articles published in EJCI in 2015. Eur J Clin Invest. 2017 Oct;47(10):775-788. doi: 10.1111/eci.12819. PMID: 28960328.
Copy Download .nbib Format: NLM
Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases.

Patient preference and adherence

Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, Mecchia M.
PMID: 30410311
Patient Prefer Adherence. 2018 Oct 16;12:2153-2168. doi: 10.2147/PPA.S168458. eCollection 2018.

OBJECTIVE: To estimate preferences in relevant treatment characteristics evaluated by different groups involved in the management of patients with rheumatic diseases.SUBJECTS AND METHODS: We surveyed patients with rheumatic diseases, and rheumatologists, nurses, and pharmacists with experience in treatment with/provision...

Cite
Scalone L, Sarzi-Puttini P, Sinigaglia L, et al. Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence. 2018;12:2153-2168doi: 10.2147/PPA.S168458.
Scalone, L., Sarzi-Puttini, P., Sinigaglia, L., Montecucco, C., Giacomelli, R., Lapadula, G., Olivieri, I., Giardino, A. M., Cortesi, P. A., Mantovani, L. G., & Mecchia, M. (2018). Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient preference and adherence, 122153-2168. https://doi.org/10.2147/PPA.S168458
Scalone, Luciana, et al. "Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases." Patient preference and adherence vol. 12 (2018): 2153-2168. doi: https://doi.org/10.2147/PPA.S168458
Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, Mecchia M. Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence. 2018 Oct 16;12:2153-2168. doi: 10.2147/PPA.S168458. eCollection 2018. PMID: 30410311; PMCID: PMC6199235.
Copy Download .nbib Format: NLM
Antiphospholipid syndrome: state of the art on clinical practice guidelines.

RMD open

Limper M, Scirè CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N, Doria A, Dörner T, Fonseca JE, Galetti I, Hachulla E, Launay D, Lourenco F, Macieira C, Meroni P, Montecucco CM, Moraes-Fontes MF, Mouthon L, Nalli C, Ramoni V, Tektonidou M, van Laar JM, Bombardieri S, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Tincani A.
PMID: 30402272
RMD Open. 2018 Oct 18;4:e000785. doi: 10.1136/rmdopen-2018-000785. eCollection 2018.

Antiphospholipid syndrome (APS) is a rare disease characterised by venous and/or arterial thrombosis, pregnancy complications and the presence of specific autoantibodies called antiphospholipid antibodies. This review aims to identify existing clinical practice guidelines (CPG) as part of the ERN...

Cite
Limper M, Scirè CA, Talarico R, et al. Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open. 2018;4:e000785doi: 10.1136/rmdopen-2018-000785.
Limper, M., Scirè, C. A., Talarico, R., Amoura, Z., Avcin, T., Basile, M., Burmester, G., Carli, L., Cervera, R., Costedoat-Chalumeau, N., Doria, A., Dörner, T., Fonseca, J. E., Galetti, I., Hachulla, E., Launay, D., Lourenco, F., Macieira, C., Meroni, P., Montecucco, C. M., Moraes-Fontes, M. F., Mouthon, L., Nalli, C., Ramoni, V., Tektonidou, M., van Laar, J. M., Bombardieri, S., Schneider, M., Smith, V., Vieira, A., Cutolo, M., Mosca, M., & Tincani, A. (2018). Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD open, 4e000785. https://doi.org/10.1136/rmdopen-2018-000785
Limper, Marteen, et al. "Antiphospholipid syndrome: state of the art on clinical practice guidelines." RMD open vol. 4 (2018): e000785. doi: https://doi.org/10.1136/rmdopen-2018-000785
Limper M, Scirè CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N, Doria A, Dörner T, Fonseca JE, Galetti I, Hachulla E, Launay D, Lourenco F, Macieira C, Meroni P, Montecucco CM, Moraes-Fontes MF, Mouthon L, Nalli C, Ramoni V, Tektonidou M, van Laar JM, Bombardieri S, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Tincani A. Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open. 2018 Oct 18;4:e000785. doi: 10.1136/rmdopen-2018-000785. eCollection 2018. PMID: 30402272; PMCID: PMC6203101.
Copy Download .nbib Format: NLM
A critical role of pentraxin 3 in severe sepsis and septic shock.

European journal of clinical investigation

Carbone F, Montecucco F, Rigamonti F.
PMID: 29131318
Eur J Clin Invest. 2018 Jan;48(1). doi: 10.1111/eci.12855. Epub 2017 Nov 28.

No abstract available.

Cite
Carbone F, Montecucco F, Rigamonti F. A critical role of pentraxin 3 in severe sepsis and septic shock. Eur J Clin Invest. 2017;48(1)doi: 10.1111/eci.12855.
Carbone, F., Montecucco, F., & Rigamonti, F. (2018). A critical role of pentraxin 3 in severe sepsis and septic shock. European journal of clinical investigation, 48(1), . https://doi.org/10.1111/eci.12855
Carbone, Federico, et al. "A critical role of pentraxin 3 in severe sepsis and septic shock." European journal of clinical investigation vol. 48,1 (2018). doi: https://doi.org/10.1111/eci.12855
Carbone F, Montecucco F, Rigamonti F. A critical role of pentraxin 3 in severe sepsis and septic shock. Eur J Clin Invest. 2018 Jan;48(1). doi: 10.1111/eci.12855. Epub 2017 Nov 28. PMID: 29131318.
Copy Download .nbib Format: NLM
Primary resistance of human patients to botulinum neurotoxins A and B.

Annals of clinical and translational neurology

Pirazzini M, Carle S, Barth H, Rossetto O, Montecucco C.
PMID: 30128321
Ann Clin Transl Neurol. 2018 Jul 17;5(8):971-975. doi: 10.1002/acn3.586. eCollection 2018 Aug.

Botulinum neurotoxin serotypes A and B are successfully used to treat a variety of human diseases characterized by hyperactive peripheral nerve terminals. However, a number of patients are primary resistant to these pharmaceuticals, without having antitoxin-neutralizing antibodies. A straightforward...

Cite
Pirazzini M, Carle S, Barth H, et al. Primary resistance of human patients to botulinum neurotoxins A and B. Ann Clin Transl Neurol. 2018;5(8):971-975doi: 10.1002/acn3.586.
Pirazzini, M., Carle, S., Barth, H., Rossetto, O., & Montecucco, C. (2018). Primary resistance of human patients to botulinum neurotoxins A and B. Annals of clinical and translational neurology, 5(8), 971-975. https://doi.org/10.1002/acn3.586
Pirazzini, Marco, et al. "Primary resistance of human patients to botulinum neurotoxins A and B." Annals of clinical and translational neurology vol. 5,8 (2018): 971-975. doi: https://doi.org/10.1002/acn3.586
Pirazzini M, Carle S, Barth H, Rossetto O, Montecucco C. Primary resistance of human patients to botulinum neurotoxins A and B. Ann Clin Transl Neurol. 2018 Jul 17;5(8):971-975. doi: 10.1002/acn3.586. eCollection 2018 Aug. PMID: 30128321; PMCID: PMC6093845.
Copy Download .nbib Format: NLM
Erratum to "Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism" [Biochem. Pharmacol. 98 (2015) 522-530].

Biochemical pharmacology

Zanetti G, Azarnia Tehran D, Pirazzini M, Binz T, Shone CC, Fillo S, Lista F, Rossetto O, Montecucco C.
PMID: 27498956
Biochem Pharmacol. 2016 Sep 01;115:152. doi: 10.1016/j.bcp.2016.07.006. Epub 2016 Jul 12.

No abstract available.

Cite
Zanetti G, Azarnia Tehran D, Pirazzini M, et al. Erratum to "Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism" [Biochem. Pharmacol. 98 (2015) 522-530]. Biochem Pharmacol. 2016;115:152doi: 10.1016/j.bcp.2016.07.006.
Zanetti, G., Azarnia Tehran, D., Pirazzini, M., Binz, T., Shone, C. C., Fillo, S., Lista, F., Rossetto, O., & Montecucco, C. (2016). Erratum to "Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism" [Biochem. Pharmacol. 98 (2015) 522-530]. Biochemical pharmacology, 115152. https://doi.org/10.1016/j.bcp.2016.07.006
Zanetti, Giulia, et al. "Erratum to "Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism" [Biochem. Pharmacol. 98 (2015) 522-530]." Biochemical pharmacology vol. 115 (2016): 152. doi: https://doi.org/10.1016/j.bcp.2016.07.006
Zanetti G, Azarnia Tehran D, Pirazzini M, Binz T, Shone CC, Fillo S, Lista F, Rossetto O, Montecucco C. Erratum to "Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism" [Biochem. Pharmacol. 98 (2015) 522-530]. Biochem Pharmacol. 2016 Sep 01;115:152. doi: 10.1016/j.bcp.2016.07.006. Epub 2016 Jul 12. PMID: 27498956.
Copy Download .nbib Format: NLM
Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects.

Journal of clinical medicine

Vuilleumier N, Pagano S, Montecucco F, Quercioli A, Schindler TH, Mach F, Cipollari E, Ronda N, Favari E.
PMID: 31443207
J Clin Med. 2019 Aug 15;8(8). doi: 10.3390/jcm8081225.

AIMS: To explore the associations between cholesterol efflux capacity (CEC), coronary artery calcium (CAC) score, Framingham risk score (FRS), and antibodies against apolipoproteinA-1 (anti-apoA-1 IgG) in healthy and obese subjects (OS).METHODS AND RESULTS: ABCA1-, ABCG1-, passive diffusion (PD)-CEC and...

Cite
Vuilleumier N, Pagano S, Montecucco F, et al. Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects. J Clin Med. 2019;8(8)doi: 10.3390/jcm8081225.
Vuilleumier, N., Pagano, S., Montecucco, F., Quercioli, A., Schindler, T. H., Mach, F., Cipollari, E., Ronda, N., & Favari, E. (2019). Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects. Journal of clinical medicine, 8(8), . https://doi.org/10.3390/jcm8081225
Vuilleumier, Nicolas, et al. "Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects." Journal of clinical medicine vol. 8,8 (2019). doi: https://doi.org/10.3390/jcm8081225
Vuilleumier N, Pagano S, Montecucco F, Quercioli A, Schindler TH, Mach F, Cipollari E, Ronda N, Favari E. Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects. J Clin Med. 2019 Aug 15;8(8). doi: 10.3390/jcm8081225. PMID: 31443207; PMCID: PMC6722652.
Copy Download .nbib Format: NLM
Research update for articles published in EJCI in 2017.

European journal of clinical investigation

Arellano-Orden E, Bacopoulou F, Baicus C, Bonfrate L, Broadbent J, Buechler C, Carbone F, Charmandari E, Davis GR, Dullaart RPF, Efthymiou V, Goeser F, Goswami N, Jong GP, Lichtenauer M, Liou YS, Lutz P, Maeng M, Mert GÖ, Mert KU, Montecucco F, Ndrepepa G, Olesen KKW, Oliveira P, Perton FG, Portincasa P, Rodriguez-Panadero F, Schernthaner C, Schutte R.
PMID: 31524285
Eur J Clin Invest. 2019 Oct;49(10):e13163. doi: 10.1111/eci.13163. Epub 2019 Sep 16.

No abstract available.

Cite
Arellano-Orden E, Bacopoulou F, Baicus C, et al. Research update for articles published in EJCI in 2017. Eur J Clin Invest. 2019;49(10):e13163doi: 10.1111/eci.13163.
Arellano-Orden, E., Bacopoulou, F., Baicus, C., Bonfrate, L., Broadbent, J., Buechler, C., Carbone, F., Charmandari, E., Davis, G. R., Dullaart, R. P. F., Efthymiou, V., Goeser, F., Goswami, N., Jong, G. P., Lichtenauer, M., Liou, Y. S., Lutz, P., Maeng, M., Mert, G. �. �., Mert, K. U., Montecucco, F., Ndrepepa, G., Olesen, K. K. W., Oliveira, P., Perton, F. G., Portincasa, P., Rodriguez-Panadero, F., Schernthaner, C., & Schutte, R. (2019). Research update for articles published in EJCI in 2017. European journal of clinical investigation, 49(10), e13163. https://doi.org/10.1111/eci.13163
Arellano-Orden, Elena, et al. "Research update for articles published in EJCI in 2017." European journal of clinical investigation vol. 49,10 (2019): e13163. doi: https://doi.org/10.1111/eci.13163
Arellano-Orden E, Bacopoulou F, Baicus C, Bonfrate L, Broadbent J, Buechler C, Carbone F, Charmandari E, Davis GR, Dullaart RPF, Efthymiou V, Goeser F, Goswami N, Jong GP, Lichtenauer M, Liou YS, Lutz P, Maeng M, Mert GÖ, Mert KU, Montecucco F, Ndrepepa G, Olesen KKW, Oliveira P, Perton FG, Portincasa P, Rodriguez-Panadero F, Schernthaner C, Schutte R. Research update for articles published in EJCI in 2017. Eur J Clin Invest. 2019 Oct;49(10):e13163. doi: 10.1111/eci.13163. Epub 2019 Sep 16. PMID: 31524285.
Copy Download .nbib Format: NLM
Open Access Publications is our mission in 2022: perspective from the editors of the European Journal of Clinical Investigation.

European journal of clinical investigation

Montecucco F, Nathoe H.
PMID: 34889464
Eur J Clin Invest. 2022 Jan;52(1):e13724. doi: 10.1111/eci.13724. Epub 2021 Dec 10.

No abstract available.

Cite
Montecucco F, Nathoe H. Open Access Publications is our mission in 2022: perspective from the editors of the European Journal of Clinical Investigation. Eur J Clin Invest. 2021;52(1):e13724doi: 10.1111/eci.13724.
Montecucco, F., & Nathoe, H. (2022). Open Access Publications is our mission in 2022: perspective from the editors of the European Journal of Clinical Investigation. European journal of clinical investigation, 52(1), e13724. https://doi.org/10.1111/eci.13724
Montecucco, Fabrizio, and Nathoe, Hendrik. "Open Access Publications is our mission in 2022: perspective from the editors of the European Journal of Clinical Investigation." European journal of clinical investigation vol. 52,1 (2022): e13724. doi: https://doi.org/10.1111/eci.13724
Montecucco F, Nathoe H. Open Access Publications is our mission in 2022: perspective from the editors of the European Journal of Clinical Investigation. Eur J Clin Invest. 2022 Jan;52(1):e13724. doi: 10.1111/eci.13724. Epub 2021 Dec 10. PMID: 34889464.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 151 entries